Model for end‐stage liver disease exceptions in the context of the french model for end‐stage liver disease score–based liver allocation system

Claire Francoz, Jacques Belghiti, Denis Castaing, Olivier Chazouillères, Jean‐Charles Duclos‐Vallée, Christophe Duvoux, Jan Lerut, Yves‐Patrice Le Treut, Richard Moreau, Ameet Mandot, Georges Pageaux, Didier Samuel, Dominique Thabut, Dominique Valla, François Durand – 21 June 2011 – Model for End‐Stage Liver Disease (MELD) score–based allocation systems have been adopted by most countries in Europe and North America. Indeed, the MELD score is a robust marker of early mortality for patients with cirrhosis.

Can positron emission tomography with the dual tracers [11C]acetate and [18F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?

Tan To Cheung, See Ching Chan, Chi Lai Ho, Kenneth Siu Ho Chok, Albert Chi Yan Chan, William Wei Sharr, Kelvin Kwok Chai Ng, Ronnie Tung Ping Poon, Chung Mau Lo, Sheung Tat Fan – 17 June 2011 – Microvascular invasion is a poor prognostic indicator of the recurrence of hepatocellular carcinoma (HCC) after surgical treatment. Positron emission tomography (PET) with [18F]fludeoxyglucose ([18F]FDG) as a tracer has been employed to predict the prognosis before surgery for various kinds of tumors, but it has not been found to be sensitive enough for HCC.

Genome‐wide copy number analyses identified novel cancer genes in hepatocellular carcinoma

Deshui Jia, Lin Wei, Weijie Guo, Ruopeng Zha, Meiyan Bao, Zhiao Chen, Yingjun Zhao, Chao Ge, Fangyu Zhao, Taoyang Chen, Ming Yao, Jinjun Li, Hongyang Wang, Jianren Gu, Xianghuo He – 17 June 2011 – A powerful way to identify driver genes with causal roles in carcinogenesis is to detect genomic regions that undergo frequent alterations in cancers. Here we identified 1,241 regions of somatic copy number alterations in 58 paired hepatocellular carcinoma (HCC) tumors and adjacent nontumor tissues using genome‐wide single nucleotide polymorphism (SNP) 6.0 arrays.

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

Neeraj Bhala, Paul Angulo, David van der Poorten, Eric Lee, Jason M. Hui, Giorgio Saracco, Leon A. Adams, Phunchai Charatcharoenwitthaya, Joanne H. Topping, Elisabetta Bugianesi, Christopher P. Day, Jacob George – 17 June 2011 – Information on the long‐term prognosis of nonalcoholic fatty liver disease (NAFLD) is limited. We sought to describe the long‐term morbidity and mortality of patients with NAFLD with advanced fibrosis or cirrhosis by prospectively studying 247 such patients from four international centers (in Australia, USA, UK and Italy).

Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era

Carl L. Berg, Robert M. Merion, Tempie H. Shearon, Kim M. Olthoff, Robert S. Brown, Talia B. Baker, Gregory T. Everson, Johnny C. Hong, Norah Terrault, Paul H. Hayashi, Robert A. Fisher, James E. Everhart – 17 June 2011 – Receipt of a living donor liver transplant (LDLT) has been associated with improved survival compared with waiting for a deceased donor liver transplant (DDLT).

Aldo‐keto reductase‐7A protects liver cells and tissues from acetaminophen‐induced oxidative stress and hepatotoxicity

Munzir M.E. Ahmed, Tao Wang, Yu Luo, Shuilong Ye, Qiao Wu, Zongsheng Guo, Bill D. Roebuck, Thomas R. Sutter, James Y. Yang – 17 June 2011 – Aldo‐keto reductase‐7A (AKR7A) is an enzyme important for bioactivation and biodetoxification. Previous studies suggested that Akr7a might be transcriptionally regulated by oxidative stress‐responsive transcription factor nuclear factor erythroid 2 p45‐related factor 2 (Nrf2), a protein highly responsive to acetaminophen (APAP) or its intermediate metabolite, N‐acetyl‐p‐benzoquinoneimine (NAPQI).

Subscribe to